These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Development of [ Wen X; Xu P; Zeng X; Liu J; Du C; Zeng X; Cheng X; Wang X; Liang Y; Zhao T; Yang H; Li H; Meng L; Fang J; Liu H; Zhou Z; Zhang J; Zhang X; Guo Z; Chen X Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2846-2860. PubMed ID: 37097443 [TBL] [Abstract][Full Text] [Related]
9. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer. Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290 [TBL] [Abstract][Full Text] [Related]
12. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells. Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023 [TBL] [Abstract][Full Text] [Related]
13. Hetero-bivalent agents targeting FAP and PSMA. Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291 [TBL] [Abstract][Full Text] [Related]
14. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629 [TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of a New Series of Albumin-Binding Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410 [TBL] [Abstract][Full Text] [Related]
16. Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent Wang Z; Jacobson O; Tian R; Mease RC; Kiesewetter DO; Niu G; Pomper MG; Chen X Bioconjug Chem; 2018 Jul; 29(7):2309-2315. PubMed ID: 29865797 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer. Lesniak WG; Boinapally S; Banerjee SR; Behnam Azad B; Foss CA; Shen C; Lisok A; Wharram B; Nimmagadda S; Pomper MG Mol Pharm; 2019 Jun; 16(6):2590-2604. PubMed ID: 31002252 [TBL] [Abstract][Full Text] [Related]
18. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Umbricht CA; Benešová M; Schibli R; Müller C Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274 [TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of a Novel High-Affinity Radioligand [ Bezverkhniaia E; Kanellopoulos P; Abouzayed A; Larkina M; Oroujeni M; Vorobyeva A; Rosenström U; Tolmachev V; Orlova A Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139219 [TBL] [Abstract][Full Text] [Related]
20. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Benešová M; Umbricht CA; Schibli R; Müller C Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]